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DOI 10.1016/j.ccr.2011.05.005SUMMARYAngioproliferative tumors induced by the Kaposi’s sarcoma-associated herpesvirus (KSHV) have been
successfully treated with rapamycin, which provided direct evidence of the clinical activity of mTOR inhibi-
tors in human malignancies. However, prolonged mTOR inhibition may raise concerns in immunocompro-
mised patients, including AIDS-Kaposi’s sarcoma (KS). Here, we explored whether KSHV oncogenes deploy
cell type-specific signaling pathways activating mTOR, which could be exploited to halt KS development
while minimizing immune suppressive effects. We found that PI3Kg, a PI3K isoform exhibiting restricted
tissue distribution, is strictly required for signaling from the KSHV-encoded vGPCR oncogene to Akt/
mTOR. Indeed, by using an endothelial-specific gene delivery systemmodeling KS development, we provide
genetic and pharmacological evidence that PI3Kgmay represent a suitable molecular target for therapeutic
intervention in KS.INTRODUCTION
The activation of the PI3K/Akt/mTOR-signaling axis may repre-
sent one of the most frequent events in cancer (Bunney and
Katan, 2010; Manning and Cantley, 2007; Sabatini, 2006), hence
prompting the development of molecular inhibitors of this
biochemical route as promising anticancer agents, many of
which are already in advanced stages of clinical evaluation (Bun-
ney and Katan, 2010; Dancey, 2010; Guertin and Sabatini, 2007).
In this regard the effectiveness of an mTOR inhibitor, rapamycin,
as an antitumoral agent was first demonstrated for the treatment
of an angioproliferative disease known as Kaposi’s sarcoma (KS)
arising in immunosuppressed renal transplanted patients (Stal-
lone et al., 2005). Rapamycin and its analogs (rapalogs) are
currently under intense investigation for their clinical efficacy in
numerous cancer types (Dancey, 2010). Four clinical manifesta-
tions of KS differ in their aggressiveness and epidemiology (Ga-
nem, 2010). The mildest form, classic KS, affects elder men ofSignificance
Activation of the PI3K-Akt pathway resulting in mTOR stimul
hence, small molecule inhibitors of this biochemical route rep
andmetabolic functions of mTORmay limit the clinical benefits
of a tissue-restricted PI3K isoform, PI3Kg, by the KSHV-encode
contributing to oncogenic signaling to mTOR, while sparing t
indicate that PI3Kg may represent a suitable therapeutic tar
including tumor-induced angiogenesis, thereby avoiding the p
inhibition.the Mediterranean area. Endemic KS is much more aggressive
and is now the leading cancer affecting children and young
men in subequatorial Africa. Iatrogenic and AIDS-associated
KS are the most aggressive, and related to immunosuppression
due to organ transplantation or HIV infection, respectively (Ga-
nem, 2010; Mesri et al., 2010).
The Kaposi sarcoma-associated herpesvirus (KSHV), also
known as human herpesvirus 8 (HHV-8), is the etiologic agent
of KS (Chang et al., 1994; Ganem, 2010; Mesri et al., 2010).
KSHV encodes 84 genes and 12 miRNAs, many of which harbor
oncogenic potential (Ganem, 2010). Among them, several lines
of evidence support the role for a constitutively active, virally en-
coded G protein-coupled receptor (vGPCR) in KS initiation and
progression (Bais et al., 2003; Mesri et al., 2010; Montaner
et al., 2003; Yang et al., 2000). vGPCR activates an intricate
network of molecular-signaling events, driving both the aberrant
growth of endothelial cells and the paracrine transformation of
endothelial-derived cells expressing KSHV latent genes (Mesriation is one of the most frequent events in human cancer;
resent attractive anticancer agents. However, key immune
of its specific inhibitors for cancer treatment. The activation
d vGPCR oncogene enabled inhibition of an upstream event
he normal physiological functions of mTOR. These findings
get for KS and for a myriad of angioproliferative diseases,
otential toxicities associated with mTOR, Akt, or pan PI3K
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Figure 1. vGPCR Induces the PI3Kg-Dependent Activation of mTOR
(A) Serum-starved murine immortal endothelial cells (SVECs) were pretreated with inhibitors and then stimulated with IL8 or VEGF165 (see Supplemental
Experimental Procedures for details). vGPCR, SVECs stably expressing vGPCR.
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PI3Kg Inhibition Prevents KSet al., 2010). The PI3K/Akt/mTOR pathway represents one of the
most prominent oncogenic mechanisms deployed by vGPCR,
as revealed by genetically defined animal models for KS (Sodhi
et al., 2004, 2006). These findings provided the foundation for
the evaluation and clinical success of the use of mTOR inhibitors
for iatrogenic KS lesions, achieving a rapid and complete remis-
sion in all the patients involved in the initial study (Stallone et al.,
2005). The effectiveness of rapamycin in iatrogenic KS may
result from a rare convergence of antitumoral and desirable ther-
apeutic immunosuppressive properties; hence, rapamycin is
now becoming the standard of care for renal transplanted
patients developing KS (Stallone et al., 2008). However, pro-
longed use of mTOR inhibitors may raise concerns for those
affected by the endemic form of this disease and for patients
with AIDS that are already immunocompromised due to their
elevated viral load. In this regard, the possibility still exists that
KSHV oncogenes may deploy cell type-specific signaling events
leading to mTOR activation that can be exploited to halt KS
development while minimizing immune suppressive effects.
Thus, we set up to investigate the molecular mechanism by
which vGPCR initiates the oncogenic activation of mTOR in
endothelial cells, aimed at identifying alternative molecular
targets for the treatment of angioproliferative diseases.
RESULTS
Expression of vGPCR in immortalized murine (SVECs) and
human (HMEC-1) endothelial cells stimulates Akt and mTOR
potently, as judged by the accumulation of phosphorylated Akt
(pAktS473) and S6 (pS6), the latter a downstream target of
mTOR (Figure 1A; see Figure S1A available online). This was
accompanied by morphological changes (Figure S1B), in-
creased cell size (Figure S1C), and increased survival upon
growth factor deprivation (Figure S1D). Activation of Akt and
mTOR required PI3K because it is sensitive to the PI3K inhibitor
wortmannin, whereas pS6 accumulation was blocked by rapa-
mycin that inhibits mTOR. Inhibition of heterotrimeric G proteins
of the Gi family by pertussis toxin (PTX) partially prevented the
activation of Akt and mTOR by vGPCR. The CXC chemokine
IL8, which acts on endogenous Gi-coupled CXCR2 receptors,
and VEGF, which stimulates its cognate tyrosine kinase recep-
tors, were used as positive and negative controls, respectively.(B) SVEC vGPCR cells expressing YFP-PH (see Supplemental Experimental Proc
equal 20 mm.
(C) Analysis of the expression of the PI3K a, b, and g isoforms in SVECs. Expre
expressing 293T cells were used as controls.
(D) siRNA-mediated knockdown of different PI3K isoforms in SVECs. SVECswere
Exponentially growing cultures were analyzed by western blot after 5 days.
(E) PI3Kg mediates the activation of Akt and mTOR downstream of vGPCR. SV
indicated after 5 days.
(F) PI3Kg knockdown selectively impairs the activation of Akt and mTOR downs
(vGPCR) cells were treated as depicted and analyzed by western blotting.
(G) shRNA-mediated knockdown of PI3Kg reduces the activation of Akt and m
transfected with PI3Kg shRNA expression vectors for 72 hr were treated as desc
experiment is shown.
(H) SVEC vGPCR cells stably expressing a PI3Kg shRNA show reduced tumorige
Supplemental Experimental Procedures) were injected subcutaneously into the
tumor weight (n = 8) ± SEM (*p% 0.001) at each time point.
(I) Gross morphology of the tumor xenografts from (H).
See also Figure S1.These results were further confirmed using the pleckstrin
homology (PH) domain from Akt fused to YFP, which can be
used to monitor the presence of phosphatidylinositol 3,4,5-tri-
sphosphate (PIP3) at the plasma membrane. IL8 treatment
or the expression of vGPCR induced the relocalization of the
PH-YFP construct from the cytosol to the plasma membrane
(Figure 1B; Figure S1E), which was sensitive to wortmannin
and PTX, but not to rapamycin. The residual activity after PTX
treatment may reflect the more limited ability of vGPCR to signal
to Akt by other PTX-insensitive G proteins. We can conclude that
a Gi-dependent PI3K activity is largely required for the activation
of the Akt/mTOR pathway by vGPCR.
Four different class I PI3K catalytic subunits have been
described in mammalian cells, which display divergent regula-
tion and patterns of expression. PI3Ka, b, and d are regulated
by tyrosine kinase receptors through interaction with their regu-
latory subunits, with PI3Ka and b being expressed ubiquitously
and PI3Kd expressed mainly by leukocytes (Engelman et al.,
2006). PI3Kg exhibits restricted tissue distribution and is acti-
vated by GPCRs by the interaction of its catalytic (p110g) and
regulatory subunit (p101) with Gbg subunits (Lopez-Ilasaca
et al., 1997). PI3Ka, b, and g isoforms were readily detectable
in endothelial cells (Figure 1C; Figure S1A), as reported (Morello
et al., 2009), whereas PI3Kd was undetectable by western blot-
ting and qPCR (data not shown). PI3Kg knockdown with specific
siRNAs resulted in a dramatic decrease in the activation of Akt/
mTOR in endothelial cells expressing vGPCR (Figures 1D and
1E), whereas knockdown of PI3Ka or PI3Kb had only a limited
effect. In contrast, PI3Kg siRNA did not interfere with the ability
to stimulate Akt/mTOR upon VEGF165 treatment (Figure 1F).
Because PI3Kg is expressed in human KS lesions (Figure S1F),
we hypothesized that PI3Kg may represent an attractive candi-
date to transduce the signal initiated by vGPCR to Akt/mTOR
in endothelial-derived tumor cells. Based on these findings, we
analyzed the impact of PI3Kg on vGPCR-induced tumorigenesis
in endothelial xenograft models (Montaner et al., 2003). We first
identified PI3Kg short hairpin RNAs (shRNAs) whose stable
expression efficiently knocks down the expression of PI3Kg (Fig-
ure 1G), and reduced the activation of Akt andmTOR in response
to either IL8 treatment or vGPCR cotransfection. Remarkably,
knockdown of PI3Kg greatly impaired the ability of vGPCR to
form tumors in nude mice when compared to shRNA-expressingedures) were treated as indicated. See quantification in Figure S1. Scale bars
ssion of the different PI3K isoforms was analyzed by western blotting. Over-
transfected with siRNAs as depicted (Supplemental Experimental Procedures).
EC vGPCR cells transfected as in (D) were analyzed by western blotting as
tream of vGPCR, but not VEGF165. SVEC (Control, VEGF) and SVEC vGPCR
TOR induced by IL8 and vGPCR expression. SVEC and SVEC vGPCR cells
ribed in Experimental Procedures. A western blot analysis of a representative
nesis in nude mice. One million SVEC vGPCR PI3Kg or GFP shRNA cells (see
flanks of nude mice and allowed to form tumors. Graph represents the mean
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PI3Kg Inhibition Prevents KScontrol cells (Figures 1H and 1I). Together, these results suggest
that PI3Kgmay play an essential role in vGPCR-induced activa-
tion of Akt/mTOR and in vGPCR-initiated sarcomagenesis.
We next sought to challenge these observations in a geneti-
cally defined in vivo KS model. In particular we have previously
generated genetically engineered animals expressing the
receptor for the avian leukosis virus (ALV) Tva under the control
of the Tie2 endothelial-specific promoter (Figure 2A) (Montaner
et al., 2003). In this system, infection of Tie2-Tva mice with
ALV-derived RCAS retroviruses encoding vGPCR or the potent
oncogene polyoma middle T antigen (PyMT) induces the Tva-
dependent death of mice within only a few weeks (Montaner
et al., 2003). We backcrossed this animal line into a PI3Kg
knockout background (Hirsch et al., 2000) generating mice
bearing none (+/+), hemizygous (/+), and homozygous (/) dele-
tion of this gene. Of note, PI3Kg knockout mice are viable and
display only reduced inflammatory responses and impaired
neutrophil and monocyte migration in vivo (Ruckle et al., 2006).
Infection with RCAS PyMT resulted in the deaths of approxi-
mately 60% of the TVA-positive mice within 50 days postinfec-
tion, regardless of their genotype for PI3Kg (Figure 2B), in
agreement with the mechanism of action of this viral oncogene,
involving PI3Ka and PI3Kb (Dilworth, 2002). However, when
RCAS vGPCR retroviruses were injected, 77.7% of the TVA(+)/
PI3K+/+ mice died within 70 days (median survival 20 days; n =
9), but only 20% of the TVA(+)/PI3Kg+/ died after 150 days
(n = 10; p = 0.0024; with respect to PI3K+/+ mice), whereas all
of the TVA(+)/PI3Kg/ mice survived (n = 7; p = 0.0004; with
respect to PI3K+/+ mice) without showing signs of disease,
even after 9 months of observation. The cause of death was
attributed to the presence of multiple internal angioproliferative
lesions. Those TVA(+)/PI3Kg+/+ animals that did not die within
the initial 70 day period (22.3%) invariably started developing
external and internal KS-like lesions after 6months, in agreement
with previous reports (Montaner et al., 2003), but no PI3K/+ and
PI3K/ mice developed lesions even after prolonged observa-
tion (Figure 2C).
These findings provided a strong rationale for exploring
whether pharmacological inhibition of PI3Kg represents a thera-
peutic strategy to treat KS. As a proof of principle, we assessed
whether AS-605240, a widely used PI3Kg inhibitor, can prevent
vGPCR-induced sarcomagenesis. AS-605240 induced a re-
markable and dose-dependent inhibition of Akt and mTOR
activation in endothelial cells expressing vGPCR (Figure 3A; Fig-
ure S2A). We further examined the function of this PI3Kg inhibitor
by analyzing the subcellular localization of GFP-FoxO1, which is
excluded from the nucleus upon phosphorylation by Akt (Brunet
et al., 2004). As shown in Figures 3B and 3C, AS-605240 in-
hibited Akt downstream of vGPCR, as depicted by the nuclear
localization of GFP-FoxO1, using as a control a nuclear-localized
FoxO1 mutant (GFP-FoxO1 AAA) that is resistant to Akt-medi-
ated inactivation. Treatment with rapamycin led to only a subtle
decrease in Akt activity (Figure 3D), probably reflecting a delayed
inhibition of the mTOR complex 2 by rapamycin (Laplante and
Sabatini, 2009). Furthermore, treatment of vGPCR-expressing
cells with AS-6052540 resulted in a dose-dependent inhibition
of proliferation and decreased viability (Figure S2B). In addition
to promoting the direct transformation of endothelial cells,
vGPCR expression can promote the tumoral growth of endothe-808 Cancer Cell 19, 805–813, June 14, 2011 ª2011 Elsevier Inc.lial cells, including those expressing latent KSHV transcripts in
a paracrine fashion (Mesri et al., 2010; Montaner et al., 2003).
This observation prompted us to explore the potential role of
PI3Kg in vGPCR-initiated paracrine signaling. For this analysis
we took advantage of prior observations that vGPCR-expressing
cells promote the proliferation and activation of NFkB of endo-
thelial cells in a paracrine fashion. As shown in Figures S2C
and S2D, inhibition of PI3Kg in vGPCR-expressing endothelial
cells by the use of specific shRNAs or by the use of PI3Kg inhib-
itors nearly abolished the ability of vGPCR-expressing cells to
release pro-proliferative (Figures S2C and S2D) and NFkB-acti-
vating (Figure S2E) soluble factors.
To test the potential therapeutic properties of PI3Kg inhibition,
nude mice bearing endothelial-vGPCR tumors were treated
with AS-605240, showing a marked reduction in tumor growth
(Figure 4A) with minimal signs of toxicity (2.11% ± 0.9% body
weight loss after 5 days). The impact of PI3Kg inhibition was
found to be highly specific under these conditions (Figure 4B)
because AS-605240 did not inhibit AktS473 or S6 phosphoryla-
tion caused by PyMT expression (Figure 4C) or affect the growth
of SVEC-PyMT tumor xenografts (Figure 4D). Inhibition of the
mTORpathway as judged by pS6 immunostaining was complete
24 hr after the initiation of the treatment (Figure 4E), to an extent
similar to that seen with rapamycin. We also generated endothe-
lial cells expressing vGPCR and the red fluorescent mCherry
protein, which allowed visualizing the tumor growth in real
time. Treatment with both rapamycin and AS-605240 greatly
reduced both the size and fluorescence of the tumors to the
same extent (Figures 4F and 4G). Further analysis of tumor biop-
sies revealed that both treatments induced a marked reduction
of cell proliferation as measured by Ki-67 staining and increased
the number of apoptotic cells, as determined by active caspase
3 (Figure 4H). Taken together, these results indicate that PI3Kg
inhibition with AS-605240 is at least as effective as rapamycin
at reducing the activity of mTOR, resulting in reduced cell prolif-
eration and the apoptotic demise of cancer cells and the conse-
quent tumor regression.
Collectively, in vitro and in vivo experiments using endothelial
cells, tumor xenografts, and endothelial-specific gene delivery
systems in genetically defined animals support the key role of
the vGPCR-PI3Kg signaling axis in KS initiation and progression,
hence representing a candidate molecular target for pharmaco-
logical intervention in KS.
DISCUSSION
The dissection of the dysregulated signaling networks leading to
tumor initiation and malignant progression has recently afforded
the opportunity of developing molecular-targeted options for
cancer prevention and treatment. Recent studies have high-
lighted the central role of the PI3K/Akt/mTOR pathway in some
of the most prevalent human neoplasias (Bunney and Katan,
2010). In this regard, each PI3K isoform may perform distinct
functions (Engelman et al., 2006; Vanhaesebroeck et al., 2005),
thus suggesting that their selective inhibition may provide thera-
peutic opportunities in specific disease conditions while limiting
their side effects. For example, PI3Kd, which is expressed in few
immune-derived cells, is now being evaluated as a specific
target for multiple hematologic malignancies (Ameriks and
BA
C
Tie2 EnhancerTvaTie2P
Endothelial cell
TVA
receptor
RCAS retrovirus
Tissue –speciﬁc
oncogene
expression
0 50 100 150
Time (d)
n.s.
0
50
100
%
Su
rv
iv
al
RCAS PyMT
P=0.0004 P=0.0024
0
50
100
%
Su
rv
iv
al
0 50 100 150
Time (d)
RCAS vGPCR
TVA/PI3Kγ -/+ TVA/PI3Kγ -/-TVA/PI3Kγ+/+ WT/PI3Kγ -/+ WT/PI3Kγ -/-WT/PI3Kγ+/+
1 mm
1 cm
tail
heart
0.5 cm
1 mm
50 μm
50 μm
Figure 2. A Genetic Model Unveils the Requirement of PI3Kg for vGPCR-Induced Sarcomagenesis
(A) Schematic overview of the RCAS system for somatic gene transfer. Tissue-restricted expression of the ALV receptor TVA is achieved by transgenic
technology. The Tie2 promoter and enhancer sequences target the expression of TVA to endothelial tissues. RCAS viruses encoding a gene of interest are
injected into mice resulting in tissue-specific targeted infection and expression of the viral payload.
(B) Effect of the hemi- and homozygotic loss of expression of PI3Kg on animal survival after infection with RCAS virus on TIE2-TVA animals. Five-day-old mice
born from TIE2-TVA/PI3Kg-/+3 PI3Kg/+ breeding pairs were injected with RCAS-PyMT virus (5.03 107 infective units) (right panel), or RCAS vGPCR (5.03 107
infective units) (left panel). Animals’ deaths occurred naturally and were recorded and correlated to the presence of multiple internal angioproliferative lesions
during the necropsy. The dashed box depicts a representativemacroscopic lesion in the heart. The dashed lines outline typical KS-like lesions in the tail and heart,
as indicated, which are shown under higher magnification in the corresponding insets. Arrowheads show spindle cells, and arrows indicate atypical vessels.
(C) Left-upper and lower panels show gross appearance of representative KS lesions appearing in TIE2-TVAmice injectedwith RCAS vGPCR that survived longer
than 150 days. Right panels demonstrate H&E section of the lesions found in the tail and heart. Insets illustrate high-powermagnification of the same field. Several
other tissues, including lung and kidneys, displayed similar lesions.
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PI3Kg Inhibition Prevents KSVenable, 2009). Here, we provide genetic evidence that PI3Kg,
a PI3K isoform exhibiting a restricted tissue distribution and
regulated by a distinct mechanism from other Class I PI3Ks
(Morello et al., 2009), is strictly required for the growth of endo-thelial-derived tumors and the development of KS-like lesions.
Furthermore, we show that PI3Kg-specific inhibitors promote
the rapid decrease in Akt and mTOR activation caused by
expression of a KSHV oncogene, vGPCR, in endothelial cells,Cancer Cell 19, 805–813, June 14, 2011 ª2011 Elsevier Inc. 809
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Figure 3. Pharmacological Inhibition of PI3Kg
Reduces the Activity of the Akt/mTOR Pathway by
vGPCR In Vitro
(A) Serum-starved SVEC-vGPCR cells were treated with
increasing concentrations of AS-605240, a PI3Kg-specific
inhibitor, or wortmannin (Wort) for 1 hr. Protein lysates were
analyzed by western blotting. A representative blot is shown.
(B) A GFP-FoxO1 construct was used as reporter for Akt
activity. COS-7 cells were cotransfected with a vGPCR-en-
coding plasmid and GFP-FoxO1 (Control) or a GFP-FoxO1 in
which the three residues phosphorylated by Akt responsible
for its nuclear export aremutated to alanine (GFP-FoxO1 AAA).
Serum-starved cells were fixed and stained with phalloidin-
Texas red and the nuclear staining Hoechst 33342. In the
upper panel, control cells display typical GFP cytosolic local-
ization. In the lower panel, cells expressing the AAA mutant
show a strong nuclear localization of this construct. Scale bars,
25 mm.
(C) Inactivation of Akt induced by treatment with AS-605240.
COS-7 cells expressing vGPCR and GFP-FoxO1, as in (B),
were treated as indicated. AS-605240 induced a strong and
sustained inhibition of Akt, as reflected by the nuclear reloc-
alization of GFP-FoxO1, whereas rapamycin only inhibited Akt
modestly after 24 hr. Scale bars, 25 mm.
(D) Quantification of the percentage of cells displaying nuclear
translocation of the GFP-FoxO1 constructs from (B) and (C).
Bars represent the mean percentage ± SD from 3 different
samples in which at least 200 transfected cells were evaluated.
See also Figure S2.
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Figure 4. PI3Kg Inhibition Halts Tumor Growth Induced by vGPCR
(A) SVEC vGPCR xenografts were prepared as in Figure 1H. Tumors were allowed to grow for 3 weeks (average tumor weight 42.3 ± 2.3 mg), and mice were
treated with vehicle or 25mg/kg AS-605240 twice daily i.p. for 5 consecutive days. Animal weight wasmonitored for signs of toxicity. Data points represent mean
tumor weight ± SEM (n = 8). *p% 0.001.
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PI3Kg Inhibition Prevents KSthereby causing their apoptotic death and tumor regression,
probably due to impaired vGPCR-initiated direct and para-
crine-transforming mechanisms.
Extensive studies in mice lacking PI3Kg have demonstrated
that this protein is not required for normal development, life
span, or basic immune responses, unless under stress condi-
tions, and suggest that PI3Kg may represent a suitable thera-
peutic target in a variety of inflammatory and cardiovascular
diseases (Ghigo et al., 2010; Ruckle et al., 2006). Interestingly,
even the deletion of a single PI3Kg allele in heterozygous mice
was sufficient to prevent the formation of KS-like lesions and
protected the majority of the mice from KSHV vGPCR-caused
death, highlighting the exquisite sensitivity of endothelial-
derived tumors to PI3Kg inhibition. Taken together, these find-
ings raise the possibility that PI3Kg inhibitors may represent
a suitable therapeutic option to prevent or treat already-estab-
lished KS lesions, likely avoiding the potential toxicities associ-
ated with mTOR, Akt, or pan-PI3K inhibition.
KS remains the most prevalent cancer among children and
adolescents in Africa, and whereas the use of highly active anti-
retroviral therapy (HAART) has dramatically reduced the number
of AIDS-KS cases in the last decade, KS is still the most preva-
lent AIDS-associated malignancy (Ganem, 2010). Failure to
adhere to the HAART regime, aging, chronic inflammation, and
the possibility of the emergence of HAART-resistant HIV all
pose a risk of KS reemergence that we cannot afford to ignore.
In this regard, maintaining a normal immunocompetence
appears to be the most effective way to control KS. Paradoxi-
cally, the efficacy of the immunosuppressant rapamycin at treat-
ing iatrogenic KS highlights the sensitivity to targeted molecular
intervention in this angioproliferative disease despite a de-
pressed immune status (Stallone et al., 2008). This, in turn,
may facilitate the development of effective mechanism-based
therapies for KS in patients in whom the risk for complications
derived from immunosuppression outweighs the advantages of
direct mTOR inhibition. Indeed, we now show that the distinct
coupling ability of a KSHV oncogene to an endothelial-ex-
pressed PI3K isoform and the strict requirement of a functional
PI3Kg for KS development can be exploited for the development
of molecular-targeted treatment options and preventive strate-
gies for this viral-associated malignancy. The emerging role of
PI3Kg in pathological endothelial cell functions and malignant(B) Tumor xenografts of SVEC vGPCR were established as described in Experime
i.p.), or rapamycin (5 mg/kg/day i.p.), as indicated. Tumor size was measured th
(C) Western blot analysis of pAktS473 and pS6 in SVEC PyMT or SVEC vGPCR t
described in (B) and (D).
(D) Tumor xenografts of SVEC PyMTwere established and treated as in (B). Tumor
SEM. n.s., not significant.
(E) SVEC vGPCR tumor-bearingmice received one treatment with vehicle, rapamy
Tumors were excised and processed for H&E and pS6 immunohistochemistry.
Bar, 150 mm.
(F) Tumor xenografts were generated as in (A) using SVEC vGPCR cells expres
real time using in vivo fluorescence imaging. Tumors were allowed to grow for 3
(25 mg/kg), i.p. Photometric analysis of the tumors’ red fluorescence after 1
AS-605240-treated groups. Bars represent the average total flux (n = 10 tumors)
(G) Three representative animals of each group (n = 5) from (F) are shown.
(H) Tumors generated in parallel as in (A) were excised and processed for immun
Caspase3 (Active Casp3) after the indicated days of treatment. Representative a
(Supplemental Experimental Procedures). Data points represent the mean perce
812 Cancer Cell 19, 805–813, June 14, 2011 ª2011 Elsevier Inc.conversion suggests that this PI3K isoform may also represent
an attractive candidate for other angioproliferative diseases.
EXPERIMENTAL PROCEDURES
Cell Lines, Tissue Culture, DNAs, Transfections, and Reagents
SV40-immortalized murine endothelial cells (SVEC4-10) where purchased
from ATCC (Manassas, VA, USA). SVEC and COS-7 cells were cultured in
DMEM 10% fetal bovine serum supplemented with antibiotics, 5% CO2 at
37C. SVEC vGPCR cells were generated by stable transfection of pCEFL
AU5-vGPCR as reported (Montaner et al., 2003). For stable knockdown,
SVEC vGPCR cells were stably transfected with both shRNAs by cotransfec-
tion at 1:10 ratio with a Hygromycin-resistant vector (pBABE-hygro) and then
selected in 150 mg/ml Hygromycin for 2 weeks.
Animal Work
All animal studies were carried out according to NIH-approved protocols, in
compliance with the Guide for the Care and Use of Laboratory Animals.
Establishment of Tumor Xenografts in Athymic nu/nu Mice
SVEC lines were used to induce endothelial tumor xenografts in athymic mice
as described previously (Montaner et al., 2003).
TIE2-Tva transgenic animals (Montaner et al., 2003) were backcrossed into
a PI3Kg knockout background to generate the six possible combinations of
Tva and PI3Kg gene dosage. Preparation and in vivo infection with RCAS
viruses encoding PyMT and AU5-tagged vGPCR were performed as previ-
ously described (Montaner et al., 2003).
In Vivo Fluorescence Analysis
SVEC vGPCR cells were infected with a lentivirus encoding an EF-1a-driven
red fluorescent protein (pLESIP mCherry) and selected by FACS. Xenografts
arising from these cells were quantified with a Xenogen IVIS-100 system
(Caliper, Hopkinton, MA, USA) using the built-in Ds-Red filter set and 1 s expo-
sure time. Measurements were performed using Caliper’s Living Image suite.
Statistical Analysis
Data analysis was performed using GraphPad Prism version 5.01 for Windows
(GraphPad Software, San Diego, CA, USA). ANOVA followed by the Tukey
t test was used to analyze the differences between experimental groups.
Comparison of survival curves was performed by a log rank Mantel-Cox test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and two figures and can be found with this article online at doi:10.1016/j.ccr.
2011.05.005.ntal Procedures. Tumors were treated with vehicle, AS-605240 (25 mg/kg/day
ree times a week. Values represent mean tumor weight ± SEM.
umor tissues collected 4 hr after i.p. injection of the indicated treatments, as
size wasmeasured three times a week. Values represent mean tumor weight ±
cin (5mg/kg, i.p.), or AS-605240 (25mg/kg, i.p.) andwere sacrificed 24 hr after.
A representative field is shown from four tumor samples with similar results.
sing the red fluorescent protein mCherry. Tumor growth can be monitored in
weeks and then treated daily with vehicle, rapamycin (5 mg/kg), or AS-605240
month of treatment shows marked reduction in size in the rapamycin- and
± SEM. *p% 0.01.
ostainings for the proliferation marker Ki-67 and the apoptotic marker cleaved
reas of every preparation were automatically quantified by software analysis
ntage ± SEM of positive cells in each preparation.
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